Horizon Shares Halted Ahead Of FDA Dermatologic and Ophthalmic Drugs Advisory Committee Meeting To Discuss Teprotumumab For Thyroid Eye Disease; Meeting Runs From 8 a.m. To 4 p.m. EST
Benzinga Newsdesk